ATE288756T1 - Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden - Google Patents
Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werdenInfo
- Publication number
- ATE288756T1 ATE288756T1 AT97952021T AT97952021T ATE288756T1 AT E288756 T1 ATE288756 T1 AT E288756T1 AT 97952021 T AT97952021 T AT 97952021T AT 97952021 T AT97952021 T AT 97952021T AT E288756 T1 ATE288756 T1 AT E288756T1
- Authority
- AT
- Austria
- Prior art keywords
- anxiety
- receptor antagonists
- severe depression
- treat severe
- depression accompanied
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9625051A GB9625051D0 (en) | 1996-12-02 | 1996-12-02 | Therapeutic agents |
GB9701459A GB9701459D0 (en) | 1997-01-24 | 1997-01-24 | Therapeutic agents |
GB9713715A GB9713715D0 (en) | 1997-06-27 | 1997-06-27 | Therapeutic agents |
GBGB9716472.7A GB9716472D0 (en) | 1997-08-04 | 1997-08-04 | Therapeutic agents |
GBGB9721177.5A GB9721177D0 (en) | 1997-10-07 | 1997-10-07 | Therapeutic use |
PCT/EP1997/006686 WO1998024441A1 (en) | 1996-12-02 | 1997-11-25 | Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE288756T1 true ATE288756T1 (de) | 2005-02-15 |
Family
ID=27517385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97952021T ATE288756T1 (de) | 1996-12-02 | 1997-11-25 | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0941093B1 (de) |
JP (1) | JP2001504850A (de) |
AT (1) | ATE288756T1 (de) |
AU (1) | AU736042B2 (de) |
CA (1) | CA2273800A1 (de) |
DE (1) | DE69732492T2 (de) |
ES (1) | ES2236838T3 (de) |
WO (1) | WO1998024441A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1085875A1 (de) * | 1998-06-11 | 2001-03-28 | MERCK SHARP & DOHME LTD. | Verwendung von nk-1 rezeptor antagonisten zur behandlung von psychiatrischen krankheiten |
AU4278199A (en) * | 1998-06-11 | 1999-12-30 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
MX2007009571A (es) | 2005-02-25 | 2007-09-21 | Hoffmann La Roche | Tabletas con dispersion mejorada de la sustancia del farmaco. |
EP2117538A1 (de) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
WO1996005181A1 (en) * | 1994-08-15 | 1996-02-22 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as therapeutic agents |
-
1997
- 1997-11-25 WO PCT/EP1997/006686 patent/WO1998024441A1/en active IP Right Grant
- 1997-11-25 AT AT97952021T patent/ATE288756T1/de not_active IP Right Cessation
- 1997-11-25 JP JP52517298A patent/JP2001504850A/ja not_active Ceased
- 1997-11-25 EP EP97952021A patent/EP0941093B1/de not_active Revoked
- 1997-11-25 DE DE69732492T patent/DE69732492T2/de not_active Expired - Fee Related
- 1997-11-25 ES ES97952021T patent/ES2236838T3/es not_active Expired - Lifetime
- 1997-11-25 AU AU55591/98A patent/AU736042B2/en not_active Ceased
- 1997-11-25 CA CA002273800A patent/CA2273800A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2001504850A (ja) | 2001-04-10 |
WO1998024441A1 (en) | 1998-06-11 |
ES2236838T3 (es) | 2005-07-16 |
AU736042B2 (en) | 2001-07-26 |
CA2273800A1 (en) | 1998-06-11 |
DE69732492D1 (de) | 2005-03-17 |
DE69732492T2 (de) | 2006-03-30 |
AU5559198A (en) | 1998-06-29 |
EP0941093A1 (de) | 1999-09-15 |
EP0941093B1 (de) | 2005-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0893992T3 (da) | Hurtigt sönderdelende oral doseringsform | |
DE69507029D1 (de) | Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten | |
DE60022050D1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
MY116002A (en) | Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis | |
DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
CY1118924T1 (el) | Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας | |
HUP9904362A2 (hu) | Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával | |
DE59810761D1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
BG105962A (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
MXPA02003484A (es) | Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. | |
RU2001124802A (ru) | Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств | |
ATE288756T1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
DE69731658D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
HUP0300863A2 (hu) | N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény | |
ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
ATE216891T1 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
CY2499B1 (en) | Use of nk-1 receptor antagonists for treating stress disorders. | |
DE60035162D1 (de) | Einen ZNS-penetrierenden NK-1-Rezeptorantagonisten und ein angstlösendes oder antidepressives Mittel enthaltende Zusammensetzung zur Behandlung von Depression und Angst | |
ATE293975T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen | |
BR0311881A (pt) | Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão | |
MX2022006537A (es) | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0941093 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee | ||
RZN | Patent revoked |